UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(B) OR (G) OF
THE SECURITIES EXCHANGE ACT OF 1934
LIPOCINE INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 99-0370688 | |
(State of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |
675 Arapeen Drive, Suite 202 Salt Lake City, Utah | 84108 | |
(Address of principal executive offices) | (Zip code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Name of exchange on which | |
N/A | N/A |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. ¨
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following. x
Securities Act registration statement number to which the form relates: 333-190897
Securities to be registered pursuant to Section 12(g) of the Act:
Common Stock, $0.0001 par value per share
Item 1. | Description of Registrant’s Securities to be Registered. |
Lipocine Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, par value $0.0001 per share, to be registered hereunder contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-190897), as originally filed with the Securities and Exchange Commission (the “Commission”) on August 29, 2013, as subsequently amended (the “Registration Statement”), and in the prospectus included in the Registration Statement, as filed separately by the Registrant with the Commission on September 27, 2013 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus is hereby incorporated by reference herein.
Item 2. | Exhibits. |
See Exhibit Index immediately following the signature page.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Company has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
Lipocine Inc. | ||||||||
Date: October 21, 2013 | By: | /s/ Morgan Brown | ||||||
Name: | Morgan Brown | |||||||
Title: | Executive Vice President and Chief Financial Officer |
EXHIBIT INDEX
Incorporated by Reference | ||||||||||
Exhibit | Description | Form | File Date | File Number | Exhibit | |||||
3.1 | Amended and Restated Certificate of Incorporation | 8-K | July 25, 2013 | 333-178230 | 3.2 | |||||
3.2 | Amended and Restated Bylaws | 8-K | July 25, 2013 | 333-178230 | 3.3 | |||||
4.1 | Form of Common Stock certificate | 8-K | July 25, 2013 | 333-178230 | 4.1 |